Suppr超能文献

依库珠单抗/特扎卡托/依伐卡托治疗囊性纤维化患者的药物性痤疮。

Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.

机构信息

College of Pharmacy, Chicago State University, 9501 S. King Drive Douglas Hall 206, Chicago, IL 60628, United States.

Department of Pharmacy, University of Utah Hospitals and Clinics, Salt Lake City, UT, 50 North Medical Drive, Salt Lake City, UT 84103, United States.

出版信息

J Cyst Fibros. 2022 Nov;21(6):1066-1069. doi: 10.1016/j.jcf.2022.09.002. Epub 2022 Sep 8.

Abstract

Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown.

摘要

依利格鲁司他/特利格鲁司他/伊伐卡托(ELX-TEZ-IVA)是一种囊性纤维化跨膜电导调节因子(CFTR)调节剂,已被证明可改善囊性纤维化(CF)患者的肺功能并降低汗液氯化物。唯一常见的与 CFTR 调节剂相关的皮肤不良反应包括皮疹。在本病例系列中,我们描述了 19 名患者,他们在向 CF 药剂师或 CF 护理团队的其他成员报告使用该药物后出现新发或恶化的痤疮。这种不良反应的机制和频率尚不清楚。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验